Clinical bottom line
Emerging anti-CD19 chimeric antigen receptor (CAR) macrophage therapies represent a novel immunotherapeutic approach targeting B-cell malignancies, with potential infectious risks distinct from CAR T-cell therapies. Current evidence on infection risk and management in patients receiving anti-CD19 CAR macrophages is limited but suggests a need for vigilance regarding opportunistic and serious infections, including mycobacterial disease, due to macrophage modulation of host immunity. Clinicians should anticipate infectious complications overlapping with those seen in other cellular immunotherapies but also consider unique macrophage-related immune alterations. Careful infection monitoring and prophylaxis strategies warrant prospective validation as these therapies enter clinical practice.
What the evidence shows
Anti-CD19 CAR macrophage therapies are an emerging frontier in cancer immunotherapy, designed to harness macrophages’ innate immune functions to target CD19-expressing B-cell malignancies (Drew et al., 2024). Unlike CAR T-cells, macrophages may modulate the tumor microenvironment and systemic immunity differently, potentially influencing infection susceptibility.
While direct clinical data on infections in patients receiving CAR macrophages are sparse, insights can be drawn from related biologic therapies and CAR T-cell experiences. Serious infections, including mycobacterial and other opportunistic infections, have been documented in patients receiving novel biologics that modulate immune cells (Winthrop et al., 2008). The Emerging Infections Network highlighted increased risk of mycobacterial infections in patients treated with anti-TNF and other biologics, underscoring the need for vigilance in novel immune-targeting therapies.
CAR T-cell therapies targeting CD19 have been associated with infectious complications related to prolonged cytopenias, hypogammaglobulinemia, and immune dysregulation (Colton et al., 2024; Jodon et al., 2023). Molecular disease monitoring studies in relapsed/refractory B-cell lymphoma patients receiving anti-CD19 CAR T-cells emphasize the importance of infection surveillance during immune reconstitution phases (Colton et al., 2024). Although macrophages differ functionally from T-cells, their role in innate immunity suggests that CAR macrophage therapies could alter host defense mechanisms, potentially predisposing patients to infections not typically seen with CAR T-cell therapies.
Drew et al. (2024) discuss the theoretical infectious risks posed by CAR macrophages, including impaired pathogen clearance or dysregulated inflammatory responses. However, clinical data remain preliminary, and no large-scale infection surveillance studies have yet been reported for this modality.
Caveats and uncertainty
The evidence base for infection risk with anti-CD19 CAR macrophage therapies is currently limited to preclinical and early-phase clinical observations. Unlike CAR T-cell therapies, which have established infectious risk profiles from multiple cohort studies, CAR macrophage therapies lack robust clinical infection outcome data.
Extrapolations from anti-TNF biologics and CAR T-cell therapies provide hypotheses but may not fully capture the unique immunologic effects of macrophage-based therapies. The heterogeneity of macrophage phenotypes and their dual roles in inflammation and immune regulation complicate predictions of infectious risk.
Furthermore, the impact of combination regimens, prior therapies, and patient-specific factors on infection susceptibility in this context remains undefined. There is also uncertainty regarding optimal infection prophylaxis, monitoring protocols, and management strategies specific to CAR macrophage recipients.
How this may change practice
As anti-CD19 CAR macrophage therapies advance toward broader clinical use, infectious disease clinicians should prepare to integrate new monitoring and management approaches tailored to this modality. Early recognition of serious infections, including mycobacterial and opportunistic pathogens, will be critical.
Clinicians should consider baseline screening for latent infections, including tuberculosis, prior to therapy initiation, paralleling practices for other biologics with macrophage or monocyte effects (Winthrop et al., 2008). Prophylactic antimicrobials may be warranted based on emerging risk profiles, though evidence-based guidelines are not yet established.
Multidisciplinary collaboration between oncology, infectious diseases, and immunology specialists will be essential to optimize patient outcomes. Prospective registries and infection surveillance studies should be prioritized to define risk factors and inform prophylaxis and treatment protocols.
In summary, cautious infection risk assessment and proactive management strategies are advisable as anti-CD19 CAR macrophage therapies enter clinical practice, pending further evidence.